UNIVERSITY EDUCATION
2015 – now PhD candidate – Epidemiology, University of Bordeaux, France
2011-2012 Master of Public Health – Clinical Epidemiology, ISPED, University of Bordeaux, France
2000-2001 Master’s degree 1: Diploma in sanitary and social sciences, specialized in public health, Paris XI University, France
1987-1999 Doctor of Medicine, specializing in general medicine, Pitié-Salpêtrière Faculty of Medicine, Paris, France
CURRENT POSITION
March 2014 – now International trial manager & coordinator – MEREVA Inserm U1219, Bordeaux, France
Epidemiologist – IDLIC team, Inserm U1219, University of Bordeaux, France
WORK EXPERIENCE
2013 – 2014 Project manager – MEMENTO Cohort, CIC-EC7, Bordeaux, France
2012 – 2013 Project manager, CIC-EC7, ISPED, Bordeaux, France. Risk-adapted monitoring in clinical trials – European and French Clinical Research Infrastuctures Networks
2012 Epidemiology practicum, Epidemiology and Public Health Unit, Institut Pasteur, Cambodia
2010 – 2011 Country Coordinator, ESTHER program – Hospital Partnership for HIV care and treatment, Cambodia
2010 – 2011 Consultant, Epidemiology and Public Health Unit, Institut Pasteur, Cambodia
2007 – 2010 Clinical Coordinator, CAMELIA clinical trial – Cambodian Health Committee, Cambodia
2005 – 2007 Medical Coordinator, French Red Cross, HIV/AIDS programs, Cambodia
2004 – 2005 Medical Coordinator, French Red Cross, HIV/AIDS programs, Congo
2002 – 2004 Medical Coordinator, French Red Cross, PMTCT program, Congo
1998 – 2001 General practitioner in French Guyana and France
1998 Internship, cardiology department, French Guyana
1997 – 1998 Physician, Medical and Social Center, French Cooperation Mission, Bamako, Mali
1994 – 1996 Internship, Cayenne, French Guyana
Marcy O, Ung V, Goyet S, Borand L, Msellati P, Tejiokem M, Nguyen Thi NL, Nacro B, Cheng S, Eyangoh S, Pham TH, Ouedraogo AS, Tarantola A, Godreuil S, Blanche S, and Delacourt C. for the PAANTHER study group. Performance of Xpert MTB/RIF and alternative specimen collection methods for the diagnosis of tuberculosis in HIV-infected children. Clin Infect Dis. first published online February 7, 2016 doi:10.1093/cid/ciw036
Haridas V, Pean P, Jasenosky LD, Madec Y, Laureillard D, Sok T, Sath S, Borand L, Marcy O, Chan S, Tsitsikov E, Delfraissy JF, Blanc FX, Goldfeld AE; CAPRI-T (ANRS 12164) Study Team. TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB. AIDS. 2015 Jan 28;29(3):263-73.
Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, Prak N, Kim C, Lak KK, Hak C, Dim B, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; for the CAMELIA (ANRS 1295-CIPRA KH001) Study Team. Causes and Determinants of Mortality in HIV-Infected Adults With Tuberculosis: An Analysis From the CAMELIA ANRS 1295-CIPRA KH001 Randomized Trial. Clin Infect Dis. 2014 Apr 23. pii: ciu283. [Epub ahead of print]
Goyet S, Vlieghe E, Lim K, van Griensven J, Borand L, Thong P, Rammaert B, Marcy O, Tarantola A. Fluoroquinolone resistance and Mycobacterium tuberculosis: CAP guidelines play an important role. Int J Tuberc Lung Dis. 2014 May;18(5):628-30. doi: 10.5588/ijtld.13.0922.
Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, Prak N, Kim C, Lak KK, Hak C, Dim B, Nerrienet E, Fontanet A, Sok T, Goldfeld AE, Blanc FX, Taburet AM. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial). PLoS One. 2014 Mar 7;9(3):e90350. doi: 10.1371/journal.pone.0090350. eCollection 2014.
Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L, Fernandez M, Prak N, Kim C, Dim B, Nerrienet E, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; for the CAMELIA (ANRS 1295 – CIPRA KH001) Study Team. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in the camelia randomized. AIDS. 2013 Jul 3. [Epub ahead of print]
Borand L, Pheng P, Saman M, Leng C, Chea P, Sarady Ay S, Suom S, Roat Men N, Nerrienet E, Marcy O. Co-infection tuberculose et VIH: Coordination d’un essai clinique randomisé par l’Institut Pasteur du Cambodge. Med Sci (Paris). 2013 Oct;29(10):908-11. doi: 10.1051/medsci/20132910020.
Hong DN, Huyen MN, Lan NT, Duong NH, Ngo VV, Ngoc DT, Huu KT, Nguyen T, Do Chau V, Marcy O, Van de Perre P, Bañuls AL, Godreuil S. Rifampin-Resistant Mycobacterium bovis BCG-Induced Disease in HIV-Infected Infant, Vietnam. Emerg Infect Dis. 2013 Jul;19(7):1168-70.
L. Borand, D. Laureillard, Y. Madec, M. Chou, P. Pheng, O. Marcy, T. Sok, A.E Goldfeld, A-M. Taburet, F-X. Blanc, the CAMELIA (ANRS 1295-CIPRA KH001) study team. Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg. Antivir Ther (sous presse).
P. Pean, E. Nerrienet, Y. Madec, L. Borand, D. Laureillard, M. Fernandez, O. Marcy, S. Chan, K. Phon, S. Taylor, G. Pancino, F. Barré-Sinoussi and D. Scott-Algara. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood. 2012 Apr 5;119(14):3315-20. Epub 2012 Feb 17.
F.X. Blanc, T. Sok, D. Laureillard, L. Borand, C. Rekacewicz, E. Nerrienet, Y.Madec, O. Marcy, S. Chan, N. Prak, C. Kim, K.K. Lak, C. Hak, B. Dim, C.I. Sin, S. Sun, B. Guillard, B. Sar, S. Vong, M. Fernandez, L. Fox, J.F. Delfraissy, A.E. Goldfeld; CAMELIA (ANRS 1295–CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011; 365(16):1471-1481.
J. Nouhin, S. Ngin, PR. Martin, O.Marcy, L. Kruy, F. Ariey, M. Peeters, ML. Chaix, A. Ayouba, E. Nerrienet. Low prevalence of drug resistance transmitted virus in HIV Type 1-infected ARV-naive patients in Cambodia. AIDS Res Hum Retroviruses. 2009 May;25(5):543-5.
